Your browser doesn't support javascript.
loading
Development and validation of a respiratory syncytial virus multiplex immunoassay.
Marsall, Patrick; Fandrich, Madeleine; Griesbaum, Johanna; Harries, Manuela; Lange, Berit; Ascough, Stephanie; Dayananda, Pete; Chiu, Christopher; Remppis, Jonathan; Ganzenmueller, Tina; Renk, Hanna; Strengert, Monika; Schneiderhan-Marra, Nicole; Dulovic, Alex.
Afiliação
  • Marsall P; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
  • Fandrich M; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
  • Griesbaum J; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
  • Harries M; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Dayananda P; Department of Infectious Disease, Imperial College London, London, UK.
  • Chiu C; Department of Infectious Disease, Imperial College London, London, UK.
  • Remppis J; Department of Infectious Disease, Imperial College London, London, UK.
  • Ganzenmueller T; Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.
  • Renk H; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
  • Strengert M; Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.
  • Schneiderhan-Marra N; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Dulovic A; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Infection ; 52(2): 597-609, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38332255
ABSTRACT

PURPOSE:

Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins.

METHODS:

A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort.

RESULTS:

Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts.

CONCLUSION:

Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus Sincicial Respiratório Humano / Infecções por Vírus Respiratório Sincicial Tipo de estudo: Guideline / Observational_studies Limite: Adult / Child / Humans / Infant Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus Sincicial Respiratório Humano / Infecções por Vírus Respiratório Sincicial Tipo de estudo: Guideline / Observational_studies Limite: Adult / Child / Humans / Infant Idioma: En Ano de publicação: 2024 Tipo de documento: Article